The product, currently designated as FYB206, represents the first publicly announced FDA application for a Keytruda biosimilar. Under the existing licensing agreement, the acceptance of this filing mandates an undisclosed milestone payment from Zydus to Formycon. Zydus maintains exclusive commercialization rights for the drug in the United States and Canada, with a final regulatory verdict anticipated by the third quarter of 2027.
In section Market Quotes
Formycon Shares Surge on FDA Milestone for Keytruda Rival
A 13% jump in Formycon’s stock price followed the FDA’s decision to accept a review application for a biosimilar version of Merck’s cancer therapy, Keytruda. This regulatory milestone marks a significant step for the German drugmaker and its Indian partner, Zydus Lifesciences, in their bid to enter the lucrative oncology market.
While several pharmaceutical firms are racing to develop competing versions of the blockbuster treatment, the first to secure market entry stands to gain a substantial economic advantage before pricing pressures intensify. For Formycon, the recent market reaction helps recover some ground after a 14% decline in its share value earlier this year.
Comments (0)
No comments yet. Be the first!